Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil’s New Essential Medicines List Says Hello to Alzheimer’s Patch And Goodbye To Older Hep C Drugs

Executive Summary

Brazil has updated the list of essential medicines that are to be used in the public health system, the SUS.

You may also be interested in...



Latest WHO Essential Medicines List: New Drugs And A New Way Of Tackling Antibiotic Resistance

New drugs for leukemia, hepatitis C, HIV and tuberculosis have made it onto the 20th edition of the World Health Organization’s Essential Medicines List, which also features a new categorization system for antibiotics in a fresh effort to curb the rise of antibacterial resistance.

German HTA Queries Polivy Benefits Amid Lack Of Evidence

Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.

Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy

In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS121425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel